Candriam S.C.A. Personalis, Inc. Transaction History

Candriam S.C.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$7.56 - $14.3 $2.66 Million - $5.04 Million	-352,500 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$12.24 - $21.25 $130,147 - $225,951	10,633 Added 3.11%	352,500 $5.03 Million
Q3 2021 Nov 09, 2021	BUY	$16.69 - $26.05 $333,800 - $521,000	20,000 Added 6.21%	341,867 $6.58 Million
Q2 2021 Jul 20, 2021	BUY	$18.15 - $27.75 $2.01 Million - $3.07 Million	110,551 Added 52.32%	321,867 $8.14 Million
Q1 2021 Apr 29, 2021	SELL	$20.71 - $51.02 $310 - $765	-15 Reduced 0.01%	211,316 $7.43 Million
Q4 2020 Jan 22, 2021	SELL	$21.84 - $44.0 $6.47 Million - $13 Million	-296,274 Reduced 58.37%	211,331 $7.74 Million
Q3 2020 Oct 19, 2020	SELL	$13.63 - $24.12 $220,056 - $389,417	-16,145 Reduced 3.08%	507,605 $11 Million
Q2 2020 Jul 23, 2020	BUY	$7.65 - $14.11 $2.13 Million - $3.93 Million	278,443 Added 113.51%	523,750 $6.79 Million
Q1 2020 May 26, 2020	BUY	$4.75 - $12.41 $242 - $632	51 Added 0.02%	245,307 $2.61 Million
Q4 2019 Jan 21, 2020	BUY	$8.73 - $12.95 $1.26 Million - $1.87 Million	144,256 Added 142.83%	245,256 $3,000
Q3 2019 Oct 21, 2019	BUY	$14.16 - $25.34 $1.43 Million - $2.56 Million	101,000 New	101,000 $1,000

29.9M

27.5K

85.4K

Ticker PSNL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 45,918,400
Market Cap $197M
Description
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or pla...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.